Wednesday, September 19, 2007
Pharmalot has a first look, and the bill itself [big PDF]. A very quick glance through shows no obvious statements either way about preemption. Pharmalot discusses the conflicts of interest provisions (reduces the number of participants who can be allowed with them), direct-to-consumer advertising (bumps up regulations), trial publication (requires results online within a year). Not sure yet what it does with the FDA's post-marketing authorities. I'll try to take a closer look and update.